文献速递泌尿生殖与妇科肿瘤放疗

影像引导风险体积适应术后放疗的1期试验

A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-10-09

这项1期试验旨在确定生化复发前列腺癌患者接受风险体积适应大分割术后放疗时最能压缩的剂量方案,15例患者分别接受20次、15次或10次分割方案,10次分割方案(DS3)被确定为最大耐受大分割剂量方案,未观察到剂量限制性毒性,24个月时3级胃肠和泌尿生殖毒性累积发生率分别为7%和9%,生化无进展生存率在24个月和60个月均为91%。

要点

  • 10次分割方案(DS3)被确定为最大耐受大分割剂量方案:前列腺床36.4 Gy,影像定义复发灶47.1 Gy。
  • 未观察到剂量限制性毒性,24个月时3级胃肠和泌尿生殖毒性累积发生率分别为7%和9%,无4级事件。
  • 生活质量在泌尿失禁、胃肠和性功能子领域出现短暂下降,但24个月时与基线相似。

核心结论

  • 风险体积适应大分割术后放疗的最大耐受大分割剂量方案确定为DS3(10次分割,前列腺床36.4 Gy,影像定义复发灶47.1 Gy)。
  • 未观察到>3级事件,生活质量的短暂下降未持续至24个月。

研究设计与样本

  • 1期试验,采用标准3+3设计,在最大耐受大分割剂量方案处扩展6例患者。
  • 2018年1月至2023年12月共治疗15例生化复发前列腺癌患者(DS1组3例、DS2组3例、DS3组9例),中位随访48个月。

主要发现

  • 未在任何剂量方案观察到剂量限制性毒性,因此扩展在DS3进行。
  • 24个月时3级胃肠毒性和泌尿生殖毒性累积发生率分别为7%和9%,未观察到4级事件。
  • 短暂急性2级及以上胃肠毒性最常见。
  • 生活质量在泌尿失禁、胃肠和性功能子领域于研究随访期间短暂下降,但24个月时与基线相似。
  • 生化无进展生存率在24个月和60个月均为91%。

关键数值与推荐

  • 剂量方案DS1为20次分割、DS2为15次分割、DS3为10次分割,均将剂量递增至影像定义局部复发灶(73 Gy3等效剂量,按2 Gy分次)并递减至前列腺床其余部分(48 Gy3等效剂量,按2 Gy分次)。
  • 剂量限制性毒性定义为术后放疗完成后21天内持续>4天的常见不良事件评价标准v4.0版3级毒性,或此后出现的4级胃肠或泌尿生殖毒性。
  • 最大耐受大分割剂量方案DS3为10次每日分割,前列腺床36.4 Gy,影像定义复发灶47.1 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This was a phase 1 trial with the primary objective of identifying the most compressed dose schedule (DS) tolerable using risk volume-adapted, hypofractionated, postoperative radiation therapy (PORT) for biochemically recurrent prostate cancer. Secondary endpoints included biochemical progression-free survival and quality of life (QOL). METHODS AND MATERIALS: Patients were treated with 1 of 3 isoeffective DSs (DS1: 20 fractions, DS2: 15 fractions, and DS3: 10 fractions) that escalated the dose to the imaging-defined local recurrence (73 Gy3 equivalent dose in 2Gy fractions) and de-escalated the dose to the remainder of the prostate bed (48 Gy3 equivalent dose in 2Gy fractions). Escalation followed a standard 3 + 3 design with a 6-patient expansion at the maximally tolerated hypofractionated DS. Dose-limiting toxicity was defined as Common Terminology Criteria for Adverse Events v.4.0 grade (G) 3 toxicity lasting >4 days within 21 days of PORT completion or G4 gastrointestinal (GI) or genitourinary toxicities thereafter. QOL was assessed longitudinally through 24 months with the Expanded Prostate Cancer Index Composite short form. RESULTS: Between January 2018 and December 2023, 15 patients were treated (3 with DS1, 3 with DS2, and 9 with DS3). The median follow-up was 48 months. No dose-limiting toxicities were observed on any DS, and thus, expansion occurred at DS3. The cumulative incidence of G3 GI and genitourinary toxicity was 7% and 9% at 24 months, respectively, with no G4 events observed. Transient, acute G2+ GI toxicity was the most common. QOL worsened transiently during study follow-up in urinary incontinence, GI, and sexual subdomains but was similar to baseline by 24 months. The biochemical progression-free survival was 91% at both 24 and 60 months. CONCLUSIONS: The maximally tolerated hypofractionated DS for hypofractionated, risk volume-adapted PORT was determined to be DS3 (36.4 Gy to the prostate bed and 47.1 Gy to the imaging-defined recurrence in 10 daily fractions). No >G3 events were observed. Transient declines in QOL did not persist through 24 months.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Patel KR, Mena E, Rowe LS, et al. A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 39384104. doi:10.1016/j.ijrobp.2024.09.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。